14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SPB vs SKIN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Spectrum Brands Holdings, Inc. (SPB) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SPB carries a Unified Composite Score of 39.5/100 (SELL) at $83.76 (14.5x Forward P/E, 7.5% operating margin), whereas SKIN carries 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin).
Defensive Composite Rating Caution: Although SPB compares more favorably head-to-head, both SPB (39.5/100 SELL) and SKIN (34.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: SPB is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.2); meanwhile SKIN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SPB vs SKIN. Trailing 12-month operating profitability (SPB 7.5% vs SKIN 2.4%) and valuation multiples (SPB 14.5x vs SKIN 106.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Household & Personal Products value chain with $106.3M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment64.8% of Rev ($187M)
90D Engineering Disclosures0 Published
Investor FAQ SPB vs SKIN Key Questions & Quantitative Answers
As of Nov 16, 2026, Spectrum Brands Holdings, Inc. (SPB) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SPB carries a Unified Composite Score of 39.5/100 (SELL) at $83.76 (14.5x Forward P/E, 7.5% operating margin), whereas SKIN carries 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin). Defensive Composite Rating Caution: Although SPB compares more favorably head-to-head, both SPB (39.5/100 SELL) and SKIN (34.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: SPB is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.2); meanwhile SKIN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SKIN leads the Growth & Scale pillar: SPB posts -2.8% YoY revenue growth and -51.3% YoY earnings growth on $2.85B TTM revenue (40.3% gross margin, 7.5% operating margin), compared with SKIN at -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin). On trailing 12-month operating scale, SPB generates $2.85B in USD-normalized revenue versus $289M for SKIN. In operating R&D and SG&A reinvestment, SPB deploys 32.8% of Rev ($936M) (0 90-day corporate R&D disclosures) versus 64.8% of Rev ($187M) (0 disclosures) for SKIN.
SPB screens cheaper on headline valuation multiples. SPB trades at 14.5x Forward P/E, 39.9x Trailing P/E, 1.36x PEG, and 0.7x EV/Revenue (11.0% EBITDA margin), whereas SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SPB (3.0% ROE) versus SKIN (-30.1% ROE) capital efficiency.
In options market volatility and institutional positioning, SPB carries 37.0% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.96β · 43% Vol realized risk). By comparison, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.